Topic: MS

ECTRIMS 2022 HIGHLIGHTS – THURSDAY, OCTOBER 27 EDITION

October 27, 2022  

Re-evaluating the benefit-risk of high-efficacy treatment in MS

October 3, 2022  

Three biomarkers of DMT adverse effects proposed

August 25, 2022  

CLINICAL CASES IN MS – CASE 6: DIAGNOSTIC DILEMMA

August 22, 2022  

Is a cell-depleting DMT safe prior to HSCT?

August 9, 2022  

COVID-19 and MS – updated findings

July 28, 2022  

Key changes in Canadian MS care during the pandemic

July 7, 2022  

Pandemic prescribing – what changed?

July 6, 2022  

CLINICAL CASES IN MS – CASE 5: A CLINICALLY STABLE PATIENT PLANNING A PREGNANCY

June 15, 2022  

How much B cell suppression is needed in MS?

May 30, 2022